Literature DB >> 19967727

Oncogenic function of microtubule end-binding protein 1 in breast cancer.

Xin Dong1, Fangfang Liu, Lei Sun, Min Liu, Dengwen Li, Dan Su, Zhengmao Zhu, Jin-Tang Dong, Li Fu, Jun Zhou.   

Abstract

Microtubule end-binding protein 1 (EB1) is an evolutionarily conserved protein that regulates microtubule dynamics and participates in diverse cell activities. Here, we demonstrate that EB1 expression is up-regulated in human breast cancer specimens and cell lines. The level of EB1 correlates with clinicopathological parameters indicating the malignancy of breast cancer, including higher histological grade, higher pathological tumour node metastasis (pTNM) stage, and higher incidence of lymph node metastasis. Knockdown of EB1 expression remarkably inhibits cancer cell proliferation, and conversely, elevation of its expression promotes cell proliferation. Our data further show that EB1 promotes colony formation and enhances tumour growth in nude mice. In addition, EB1 stimulates Aurora-B activity in breast cancer cells, and EB1 expression correlates with increased Aurora-B activity in clinical samples of breast cancer. These findings thus suggest an oncogenic role for EB1 in breast cancer. Copyright 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19967727     DOI: 10.1002/path.2662

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  39 in total

1.  The microtubule-associated protein EB1 maintains cell polarity through activation of protein kinase C.

Authors:  Joseph M Schober; Guim Kwon; Debbie Jayne; Jeanine M Cain
Journal:  Biochem Biophys Res Commun       Date:  2011-11-19       Impact factor: 3.575

2.  Post-translational modifications regulate assembly of early spindle orientation complex in yeast.

Authors:  Daniela Hüls; Zuzana Storchova; Dierk Niessing
Journal:  J Biol Chem       Date:  2012-03-29       Impact factor: 5.157

3.  A comprehensive information database (CID) of breast cancer patients in China.

Authors:  Shuai Li; Li Fu
Journal:  Front Med       Date:  2012-05-08       Impact factor: 4.592

4.  CYLD coordinates with EB1 to regulate microtubule dynamics and cell migration.

Authors:  Dengwen Li; Jinmin Gao; Yunfan Yang; Lei Sun; Shaojun Suo; Youguang Luo; Wenqing Shui; Jun Zhou; Min Liu
Journal:  Cell Cycle       Date:  2014-01-21       Impact factor: 4.534

5.  Clinical relevance of cytoskeleton associated proteins for ovarian cancer.

Authors:  Johanna Schiewek; Udo Schumacher; Tobias Lange; Simon A Joosse; Harriet Wikman; Klaus Pantel; Marina Mikhaylova; Matthias Kneussel; Stefan Linder; Barbara Schmalfeldt; Leticia Oliveira-Ferrer; Sabine Windhorst
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-09       Impact factor: 4.553

6.  Regulation of tumor angiogenesis by the microtubule-binding protein CLIP-170.

Authors:  Xiaodong Sun; Fang Li; Bin Dong; Shaojun Suo; Min Liu; Dengwen Li; Jun Zhou
Journal:  Protein Cell       Date:  2013-04-03       Impact factor: 14.870

7.  Oxidative stress induced carbonylation in human plasma.

Authors:  Ashraf G Madian; Naomi Diaz-Maldonado; Qiang Gao; Fred E Regnier
Journal:  J Proteomics       Date:  2011-07-30       Impact factor: 4.044

8.  Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.

Authors:  Li-Ping Ge; Xi Jin; Yun-Song Yang; Xi-Yu Liu; Zhi-Ming Shao; Gen-Hong Di; Yi-Zhou Jiang
Journal:  Oncogene       Date:  2021-03-02       Impact factor: 9.867

9.  Tumor Suppressor RARRES1 Regulates DLG2, PP2A, VCP, EB1, and Ankrd26.

Authors:  Ziad J Sahab; Michael D Hall; Lihua Zhang; Amrita K Cheema; Stephen W Byers
Journal:  J Cancer       Date:  2010-06-02       Impact factor: 4.207

Review 10.  Microtubule-Binding Proteins as Promising Biomarkers of Paclitaxel Sensitivity in Cancer Chemotherapy.

Authors:  Songbo Xie; Angela Ogden; Ritu Aneja; Jun Zhou
Journal:  Med Res Rev       Date:  2015-09-01       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.